Table 1.
First-Line Recommended Agents | Non–First-Line Recommended Agents | Nonrecommended Agents | ||||
---|---|---|---|---|---|---|
Characteristic | Nitrofurantoin (n = 279 994) | TMP/SMX (n = 329 184) | Fluoroquinolone (n = 508 062) | Broad-Spectrum β-Lactam (n = 12 889) | Narrow-Spectrum β-Lactam (n = 31 178) | AMX/AMP (n = 7726) |
Age, median (IQR), years | 30 (23–37) | 29 (22–37) | 32 (24–39) | 28 (20–36) | 29 (21–36) | 30 (23–37) |
Region of residence | ||||||
Northeast | 14.0 | 13.9 | 13.7 | 14.9 | 8.9 | 19.1 |
Midwest | 20.9 | 28.9 | 21.7 | 16.1 | 23.3 | 25.0 |
South | 41.6 | 40.7 | 45.8 | 55.5 | 30.2 | 40.9 |
West | 23.5 | 16.4 | 18.8 | 13.5 | 37.7 | 15.0 |
Provider specialty | ||||||
Emergency medicine | 6.9 | 7.2 | 7.4 | 9.1 | 19.2 | 3.0 |
Internal medicine | 11.3 | 13.3 | 16.8 | 13.6 | 10.3 | 18.1 |
Family medicine and pediatrics NEC | 32.2 | 40.0 | 38.2 | 40.9 | 30.3 | 41.5 |
OBGYN | 14.2 | 4.3 | 4.2 | 4.0 | 5.1 | 5.4 |
MD/DO/NEC | 6.1 | 7.5 | 6.2 | 5.0 | 7.0 | 6.8 |
Non-MD | 5.5 | 6.7 | 4.7 | 3.7 | 2.9 | 3.4 |
Other | 20.6 | 17.8 | 19.4 | 21.7 | 23.0 | 19.4 |
Unknown | 3.2 | 3.3 | 3.0 | 2.0 | 2.2 | 2.5 |
Comorbid conditions | ||||||
COPD | 0.6 | 0.6 | 0.7 | 0.8 | 0.9 | 0.7 |
Deficiency anemias | 0.3 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 |
Depression | 1.6 | 1.6 | 1.6 | 1.6 | 1.5 | 1.3 |
Drug/alcohol abuse | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.2 |
Hypertension | 0.9 | 1.0 | 1.2 | 1.2 | 1.1 | 1.2 |
Obesity | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.5 |
Psychoses | 2.3 | 2.1 | 2.3 | 2.5 | 2.3 | 2.0 |
N = 1 169 033. Results are expressed as percentages unless otherwise indicated. Baseline covariates were assessed on the fill date of the index antibiotic prescription. Abbreviations: AMX/AMP, amoxicillin or ampicillin; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; NEC, not elsewhere classified; OBGYN, obstetrics and gynecology; TMP/SMX, trimethoprim-sulfamethoxazole.